KLOW (GHK-Cu / KPV / BPC-157 / TB-500)

Muscle/RecoveryRegenerative blendExperimental

Also known as: KLOW blend, BPC-157 + TB-500 + GHK-Cu + KPV

KLOW (GHK-Cu / KPV / BPC-157 / TB-500), also called KLOW blend or BPC-157 + TB-500 + GHK-Cu + KPV, is a regenerative blend in the Multi-Mechanism Repair class. KLOW is a compounded blend of GHK-Cu, KPV, BPC-157 and TB-500, marketed for tissue repair.

Calculate Dose

For research use only.

Key Facts

CAS
โ€”
Molecular Weight (MW)
Varies
Half-life
Varies
FDA status
Not Approved
Administration Route
Subcutaneous
Frequency
Daily
Last updated
Sep 26, 2026
Reviewed
Aug 30, 2026
Targets
Multiple (component-dependent)

Vendor price snapshot

Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Dec 2025 and Sep 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.

Vendors listing this peptide
26
Listed offers
30
Median price per mg
$1.62/mg
Typical $1.49โ€“$2.56/mg

Open calculator ยท Compare vendors

Research summary

Vendor regenerative blend (commonly BPC-157, TB-500, GHK-Cu, and KPV). Not a single drug; several components are WADA-prohibited or unapproved.

Peptide Library's KLOW (GHK-Cu / KPV / BPC-157 / TB-500) profile summarises 4 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Protocol

Dosage Range
1-2 mg total
Frequency
Daily
Cycle
4-6 weeks on, 4 off
Administration Route
Subcutaneous
Reconstitution Guide
5 mL BAC for 80 mg blend
Injection Sites
Midsection
Concentration Example
80 mg / 5 mL = 16 mg/mL
Timing Notes
Morning/post-training
Expected Onset
1-2 weeks

Not yet checked against primary sources

These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. KLOW (GHK-Cu / KPV / BPC-157 / TB-500) is queued for dosage evidence review.

Compare reported doses across the whole library

How to reconstitute KLOW (GHK-Cu / KPV / BPC-157 / TB-500)

  1. Check the vial size and diluent volume. The profile example for KLOW (GHK-Cu / KPV / BPC-157 / TB-500) is: 5 mL BAC for 80 mg blend.
  2. Swab both vial stoppers and draw the bacteriostatic water into a sterile syringe.
  3. Add the water slowly down the inside wall of the peptide vial so it does not jet onto the powder, then swirl gently until the solution is clear. Do not shake.
  4. Record the resulting concentration: 80 mg / 5 mL = 16 mg/mL.
  5. Label the vial with the date and concentration, refrigerate it (see Storage & stability below), and use the calculator preset to convert a subcutaneous dose in mcg into syringe units.

Open the peptide calculator with the KLOW (GHK-Cu / KPV / BPC-157 / TB-500) preset โ†’

Sequence & molecular data

Sequence and molecular data for KLOW (GHK-Cu / KPV / BPC-157 / TB-500)
Amino acid sequenceGHK-Cu: Gly-His-Lys-Cu; KPV: Lys-Pro-Val; BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; TB-500: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH (thymosin ฮฒ4 17โ€“23 fragment, as TB-500 is usually sold; some vendors supply full-length thymosin ฮฒ4)
Molecular formulaVaries
Molecular weightVaries
Half-lifeVaries
AppearanceWhite lyophilized powder
FormulationLyophilized Powder

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

KLOW is a compounded blend of GHK-Cu, KPV, BPC-157 and TB-500, marketed for tissue repair. The components act on separate proposed pathways: GHK-Cu on copper-dependent matrix remodelling and collagen synthesis; KPV, the C-terminal tripeptide of alpha-MSH, on NF-kB-mediated inflammatory signalling; BPC-157 on angiogenic and nitric oxide pathways in animal models; and TB-500 on actin sequestration and cell migration. As with any such blend, the combination has no mechanism beyond its parts, no pivotal trial exists for the product, and the pharmacokinetics of co-administration have not been studied. Every component is unapproved.

Origin

Commercial peptide blend.

Targets

Multiple (component-dependent)

Regulatory & research status

KLOW (GHK-Cu / KPV / BPC-157 / TB-500) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

Regulatory and research status for KLOW (GHK-Cu / KPV / BPC-157 / TB-500)
FDA statusNot Approved
AvailabilityResearch-Only
WADA (sport)Unknown / Not Listed
Library classificationResearch-Only

Benefits

Tissue repairInflammation reductionSkin rejuvenationRecovery

KLOW (GHK-Cu / KPV / BPC-157 / TB-500) side effects

Side Effects

  • Irritation
  • Nausea

Contraindications

  • Copper allergy

Stacking

Common stacking partners

CJC-1295/IpamorelinMOTS-C

Combinations that include KLOW (GHK-Cu / KPV / BPC-157 / TB-500), with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.

Storage & stability

Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.

Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freezeโ€“thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.

Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.

Read the full guide: how to store peptides before and after reconstitution โ†’

Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544โ€“575. (PMID 20143256). General guidance for research handling; not product-specific instructions.

KLOW (GHK-Cu / KPV / BPC-157 / TB-500): frequently asked questions

What is KLOW (GHK-Cu / KPV / BPC-157 / TB-500)?

Vendor regenerative blend (commonly BPC-157, TB-500, GHK-Cu, and KPV). Not a single drug; several components are WADA-prohibited or unapproved.

How does KLOW (GHK-Cu / KPV / BPC-157 / TB-500) work?

KLOW is a compounded blend of GHK-Cu, KPV, BPC-157 and TB-500, marketed for tissue repair. The components act on separate proposed pathways: GHK-Cu on copper-dependent matrix remodelling and collagen synthesis; KPV, the C-terminal tripeptide of alpha-MSH, on NF-kB-mediated inflammatory signalling; BPC-157 on angiogenic and nitric oxide pathways in animal models; and TB-500 on actin sequestration and cell migration.

Is KLOW (GHK-Cu / KPV / BPC-157 / TB-500) FDA approved?

No. KLOW (GHK-Cu / KPV / BPC-157 / TB-500) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

What is the half-life of KLOW (GHK-Cu / KPV / BPC-157 / TB-500)?

Reported half-life for KLOW (GHK-Cu / KPV / BPC-157 / TB-500) is Varies. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

What is the amino acid sequence of KLOW (GHK-Cu / KPV / BPC-157 / TB-500)?

KLOW is a blend, not a single peptide. Its components are GHK-Cu (Gly-His-Lys copper complex), KPV (Lys-Pro-Val), BPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) and TB-500, which is usually the acetylated thymosin ฮฒ4 fragment Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln rather than the full 43-residue protein. There is no single molecular formula; composition depends on the vial.

What peptides are similar to KLOW (GHK-Cu / KPV / BPC-157 / TB-500)?

Compounds most often compared with KLOW (GHK-Cu / KPV / BPC-157 / TB-500) include GHK-Cu (Copper Peptide), KPV, BPC-157 and TB-500 (Thymosin Beta-4 fragment). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial ยท Reviewed Aug 30, 2026 ยท Updated Sep 26, 2026 ยท Version 2

This KLOW (GHK-Cu / KPV / BPC-157 / TB-500) profile is compiled from published literature (4 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy ยท How profiles are compiled ยท Report an error

Track KLOW (GHK-Cu / KPV / BPC-157 / TB-500) research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android โ†’